Work needed to close gender knowledge gap

By Nick Taylor

- Last updated on GMT

Regulators, industry and academia must do more to close the knowledge gap created by a historic shortage of women in clinical trials, according to speakers at AAPS 2009.

In the wake of the thalidomide case the US Food and Drug Administration (FDA) excluded women who could become pregnant from Phase I and early Phase II trials to eliminate the risk of harm to foetuses.

Early phase research was focused on as there is insufficient safety data at this stage but the fear of harming an unborn child spilt over into Phase III and created a depression in the number of women in clinical trials.

This created various problems that interested parties have spent the past 30 years attempting to address but Pornima Sood, director of the Women's Heart Health Initiative of Abbott Vascular, believes “industry has been lagging behind​”.

Sood believes the industry must work to improve study design, recruitment and enrolment to ensure that gender proportions in clinical trials are representative of the disease’s profile in the general population.

Without these improvements Sood fears ineffective or harmful treatment regimes will reach the market and there is evidence that the knowledge gap has already been detrimental to women.

In her presentation Noel Bairey Merz, director, women’s heat center at Cedars-Sinai, said that since 1984 the mortality rate for cardiovascular disease (CVD) has been higher in women than men.

Merz and others have investigated the problem, looking at how the efficacy of treatments differs in men and women, and believes this, coupled to the efforts by regulators, academics and industry, has helped decrease female CVD mortality rate in recent years.

However, all the speakers acknowledged the need for further work. Sood and Ameeta Parekh, director of for R&D at the FDA’s Office of Women’s Health (OWH), both agreed one aspect of this must be the standardisation of clinical trial data to improve mining and analysis.

Parekh explained that the FDA has a wealth of data but it needs standardising to be useful. Currently gender is denoted in numerous different formats, such as male or M, but the FDA has launched a standardisation programme that will result in clean, usable data.

By continuing efforts to improve the understanding of gender differences Parekh hopes that “one day the knowledge gap will be closed​”.

Related news

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Overcoming rapid growth challenges with process liquid preparation

Overcoming rapid growth challenges with process liquid preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 01-Nov-2023 | Case Study

A growing contract development manufacturing organization (CDMO) was challenged with the need to quickly expand their process liquid and buffer preparation...

Why should you use clinical trial technology?

Why should you use clinical trial technology?

Content provided by Formedix | 01-Nov-2023 | White Paper

New, innovative clinical trial technology is helping to revolutionize the research landscape. COVID-19 demonstrated that clinical trials can be run much...

Related suppliers

Follow us

Products

View more

Webinars